

For our investors, current news and developments in key areas of the medical diagnostics field.

Epinex Completes Groundbreaking Survey of Diabetes Specialists

In September and October of 2005, Epinex surveyed clinical and research endocrinologists and diabetes specialists about their current diagnostic practices for Type 2 diabetes patients and their opinion of the utility of a monthly test for glycation based on glycated albumin (the Epinex G1A® test). A six-page questionnaire was sent to 3536 endocrinologists and diabetes specialists. Doctors were surveyed regarding their practice and patient load, their views on different methods of diabetes testing currently available and, following an explanation of the basic science of the Epinex G1A® Rapid Diabetes Monitoring Index Test, were asked to evaluate the potential usefulness of the test.

Physicians' responses to the survey indicated the need for a test for intermediate glycation, such as the G1A® test (62%), and broad support for the potential utility of a rapid test for glycated albumin (57% positive, 95% positive or 'not sure'). According to the survey, the G1A® test could find applicability in a number of very large markets, including screening for metabolic syndrome and control of gestational diabetes.

Of particular significance was the finding that physicians treating Type 2 diabetics would recommend a reduction in the frequency of daily blood glucose testing of 25% or more in conjunction with a monthly G1A® test. Such a reduction would save individual patients as much as \$100 per month in testing costs, and save the healthcare system billions of dollars per year. (see chart below)

The physicians surveyed expressed great interest in knowing more about the G1A® test and in participating in its development:

- 90% of physicians surveyed declared that they would be interested in knowing more about the G1A® test.
- 67% stated that they wished to participate in further evaluation of the G1A® monitoring index.
- 67% of responding physicians would recommend that diabetic patients be tested for the G1A® index.
- 61% stated their interest in participating in a focus group to discuss the topics raised in the survey and other matters relevant to the availability of a rapid test for glycated albumin.



BioDot Micro Dispenser in wet lab

COMPANY NEWS

Facility


Epinex has acquired a state-of-the-art Quantitative Non-Contact Dispenser from our technical partner, BioDot Systems of Irvine, California. This highly specialized tool dispenses nanogram quantities of the reagents and other active substances used in producing the Epinex line of rapid test products.

Epinex Explores Strategic Relationships

The Company has recently signed a confidentiality agreement with Bio-Rad, a \$1.3 billion company and one of the most significant players in the diagnostics field. Epinex is continuing to explore the potential benefits of establishing a strategic relationship with major pharmaceutical and diagnostics companies such as Bio-Rad.

PATENT NEWS

The Company's patent for the Rapid Test for Glycated Albumin, the basis for the Epinex G1A® Rapid Diabetes Monitoring Index Test, has been translated into Japanese, a major and required step for the patent to be published and granted in Japan.



Corporate Office:
Epinex Diagnostics, Inc.
2815 McGaw Avenue
Irvine, California 92614 USA
www.epinex.com

Corporate Finance:
Jeff Byrd, Vice President
Toll Free: (866) 592-3746
jeff@epinex.com



EPINEX DIAGNOSTICS INC.
CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS

FORMER CALIFORNIA CONGRESSMAN JAMES ROGAN JOINS PRESTON GATES

EpineX to benefit from Rogan's experience in three branches of government

IRVINE, CALIF. — James Rogan, former California Congressman and Director of the U.S. Patent and Trademark Office, has joined Preston Gates as a counsel in the intellectual property litigation and policy practices. Rogan's unique background adds new depth to the firm's robust intellectual property practice and further builds upon its top-10 public policy practice. Based in Orange County, Rogan will work in the firm's California and Washington, D.C. offices.

With extensive understanding of the U.S. patent system and international trade issues involving intellectual property enforcement, Rogan will work closely with the firm's intellectual property and life sciences practices to counsel clients with patent prosecution and dispute matters nationally and internationally. Rogan's extensive ties in the Orange County community and California Assembly, as well as his Congressional experience will support the firm's public policy practice.

"We are delighted to welcome Jim to the firm," said Karen Glover, Preston Gates & Ellis firm managing partner. "His background offers a rare intellectual property perspective and gives our clients access to unique insights gained through a distinguished career that spans the judicial, legislative and executive branches of government."

Rogan served as Under Secretary of Commerce and Director of the U.S. Patent and Trademark Office (USPTO) from 2001-2004. An appointee of President Bush, Rogan managed operations of the USPTO and served as the chief advisor to the President on all intellectual property matters. During his tenure, Rogan oversaw the agency's "21st Century Strategic Plan," which sought to identify new ways to reduce patent pendency and improve patent quality while creating a more effective application process. It also marked the largest reorganization in the agency's history and was widely supported by the 21st Century Intellectual Property Coalition, an alliance composed of many of the world's largest corporations.

Rogan also co-chaired the National Intellectual Property Law Enforcement Coordination Council, which oversees domestic and international intellectual property law enforcement issues among federal entities. He continues to contribute to efforts by the World Intellectual Property Organization to create a uniform international patent system.

Prior to the USPTO, Rogan served two terms as a representative from California in the U.S. House of Representatives. While in Congress, he served as Assistant Majority Whip and was one of only two members of the House to serve on both the Commerce and Judiciary Committees. Additionally, he was a member of the critical Telecommunications, Trade and Consumer Protection and Energy and Power subcommittees of the House Commerce Committee

Medical Community Seeks Better Diabetes Monitoring

Recent trends and developments in diabetes monitoring technology indicate the increasing drive towards reducing the burden of diabetes monitoring for the patient/consumer. The diagnostics industry is responding by developing better testing procedures that are less invasive and less difficult for patients to maintain on a long-term basis.

Venture capital firms are becoming aware of the opportunity represented in funding new technologies in diabetes monitoring, as demonstrated by the recent round of successful Series A financing for Oculir, a San Diego-based company that is developing a commercial non-invasive glucose testing system based on infrared measurement of the white of the eye.

We believe that this trend is positive for EpineX's prospects for raising capital, and that our technology has the potential to be an important component of the trend towards better testing procedures for diabetes.

WORLD HEALTH ORGANIZATION SAYS DIABETES BIGGER THREAT THAN BIRD FLU

DATE: October 28, 2005
www.diabetesnews.com

Diabetes looms as a larger health threat to Asians than bird flu, the World Health Organization said Wednesday, with data showing the disease will cause millions more deaths worldwide in the coming decades. "This is a global diabetes tsunami, a catastrophe, that will become the health crisis of the 21st century and could reduce life expectancy globally for the first time in 200 years," said Paul Zimmet, director of WHO's Collaborating Center for Diabetes and the International Diabetes Institute in Australia. A new WHO report, "Preventing Chronic Diseases: A Vital Investment," shows chronic diseases, dominated by diabetes, cause twice as many deaths as infectious diseases, maternal-perinatal conditions and malnutrition combined.

Without action, WHO said 388 million people globally will die from chronic diseases such as diabetes and heart disease in the next decade. Zimmet said Asia was at the heart of a global health crisis, brought about by the "Coca-Colanization" and "Nintendoization" of its countries. Based on current trends, Asia is likely to suffer social and economic devastation from an escalating diabetes epidemic, he said in a statement. Zimmet said new research shows worse medical outcomes for patients with both infectious disease and diabetes. For example, medications for HIV are causing diabetes and increased risk of heart attacks, he said. Zimmet is in Bangkok to attend the International Diabetes Federation Western Pacific Congress.



EPINEX DIAGNOSTICS INC.
CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS